...day on NASDAQ Friday, while ophthalmic play Graybug had a more modest debut on the exchange.PMV Pharmaceuticals Inc....
...above its offering price by Friday’s close.  TARGETSPRMT5 – Protein arginine methyltransferase 5 Paul Bonanos Prelude Therapeutics Inc. PMV Pharmaceuticals Inc. Graybug...

...their NASDAQ debut this year. A third, PMV Pharmaceuticals Inc....

...for companies that have gone public on NASDAQ before entering the clinic, and two of PMV Pharmaceuticals Inc.’s...
...are Nextech Invest, Viking Global Investors and Boxer Capital of Tavistock Group. Elizabeth S. Eaton, Staff Writer PMV Pharmaceuticals Inc. p53...

...Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford University Intellia Therapeutics Inc. Cortexyme Inc. Chan Zuckerberg Biohub Grail Inc. PMV Pharmaceuticals Inc. Mirum...

...promoted internally from within a healthcare VC firm in the last 15 years. Cancer company PMV Pharmaceuticals Inc....
...medical laboratory director. He was CSO and medical director at Exagen Inc. (NASDAQ:XGN). BioCentury Staff Alector Inc. Janpix Inc. PMV Pharmaceuticals Inc. Pyxis...

...PMV raises $62M series C With plans to advance its p53-targeted candidates into the clinic, PMV Pharmaceuticals Inc....
...debt reduction (see “Buysiders on Board with BMS’s Plans for Otezla Cash” ). BioCentury Staff WinterLight Labs Inc. PMV Pharmaceuticals Inc. Novo...

...commercialization manager at Knight Cancer Institute at Oregon Health & Science University. p53-targeting cancer company PMV Pharmaceuticals Inc....
...Co. (NYSE:BMY). Elizabeth S. Eaton, Staff Writer Xilio Therapeutics Inc. Amicus Therapeutics Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision...

...corporate strategy division. Hatanaka is a corporate officer and SVP, global development division. Cancer company PMV Pharmaceuticals Inc....

...stepping down. Mundipharma European Director of Commercial Operations Alberto Martinez will become CEO. Cancer company PMV Pharmaceuticals Inc....

...On Feb. 22, cancer company PMV Pharmaceuticals Inc. (Cranbury, N.J.) raised $74 million in a series B round...
...InterWest Partners , OrbiMed Advisors and Osage University Partners also participated. PMV Pharmaceuticals Inc. , Cranbury, N.J. Alicia Parker PMV Pharmaceuticals Inc....